198 related articles for article (PubMed ID: 37609458)
1. Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Siegel JS; Pearson C; Lenze EJ
Mo Med; 2023; 120(4):292-298. PubMed ID: 37609458
[TBL] [Abstract][Full Text] [Related]
2. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
Cerbo AD
Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Treatments for Anhedonia.
Klein ME; Grice AB; Sheth S; Go M; Murrough JW
Curr Top Behav Neurosci; 2022; 58():467-489. PubMed ID: 35507281
[TBL] [Abstract][Full Text] [Related]
4. Letter to the Editor: Depression As The First Symptom Of Frontal Lobe Grade 2 Malignant Glioma.
Nazlı ŞB; Sevindik M
Turk Psikiyatri Derg; 2022; 33(2):143-145. PubMed ID: 35730515
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.
Cao B; Zhu J; Zuckerman H; Rosenblat JD; Brietzke E; Pan Z; Subramanieapillai M; Park C; Lee Y; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():109-117. PubMed ID: 30611836
[TBL] [Abstract][Full Text] [Related]
6. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder.
Browne CA; Wulf H; Lucki I
Handb Exp Pharmacol; 2022; 271():493-524. PubMed ID: 33580854
[TBL] [Abstract][Full Text] [Related]
7. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
8. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
9. A brief history of antidepressant drug development: from tricyclics to beyond ketamine.
Pereira VS; Hiroaki-Sato VA
Acta Neuropsychiatr; 2018 Dec; 30(6):307-322. PubMed ID: 29388517
[TBL] [Abstract][Full Text] [Related]
10. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
[TBL] [Abstract][Full Text] [Related]
11. Immune targets for therapeutic development in depression: towards precision medicine.
Drevets WC; Wittenberg GM; Bullmore ET; Manji HK
Nat Rev Drug Discov; 2022 Mar; 21(3):224-244. PubMed ID: 35039676
[TBL] [Abstract][Full Text] [Related]
12. Novel Targets to Treat Depression: Opioid-Based Therapeutics.
Browne CA; Jacobson ML; Lucki I
Harv Rev Psychiatry; 2020; 28(1):40-59. PubMed ID: 31913981
[TBL] [Abstract][Full Text] [Related]
13. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.
Ballard ED; Wills K; Lally N; Richards EM; Luckenbaugh DA; Walls T; Ameli R; Niciu MJ; Brutsche NE; Park L; Zarate CA
J Affect Disord; 2017 Aug; 218():195-200. PubMed ID: 28477497
[TBL] [Abstract][Full Text] [Related]
14. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
[TBL] [Abstract][Full Text] [Related]
15. Anhedonia in Depression and Bipolar Disorder.
Whitton AE; Pizzagalli DA
Curr Top Behav Neurosci; 2022; 58():111-127. PubMed ID: 35397065
[TBL] [Abstract][Full Text] [Related]
16. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).
Pizzagalli DA; Smoski M; Ang YS; Whitton AE; Sanacora G; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu DV; Murrough JW; Yang H; Weiner RD; Calabrese JR; Goodman W; Potter WZ; Krystal AD
Neuropsychopharmacology; 2020 Sep; 45(10):1656-1663. PubMed ID: 32544925
[TBL] [Abstract][Full Text] [Related]
17. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
Lally N; Nugent AC; Luckenbaugh DA; Niciu MJ; Roiser JP; Zarate CA
J Psychopharmacol; 2015 May; 29(5):596-607. PubMed ID: 25691504
[TBL] [Abstract][Full Text] [Related]
18. Anhedonia in Depression and Schizophrenia: Brain Reward and Aversion Circuits.
Liang S; Wu Y; Hanxiaoran L; Greenshaw AJ; Li T
Neuropsychiatr Dis Treat; 2022; 18():1385-1396. PubMed ID: 35836582
[TBL] [Abstract][Full Text] [Related]
19. Copper and anti-anhedonic effect of ketamine in treatment-resistant depression.
Słupski J; Cubała WJ; Górska N; Słupska A; Gałuszko-Węgielnik M
Med Hypotheses; 2020 Nov; 144():110268. PubMed ID: 33254572
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine.
Adzic M; Lukic I; Mitic M; Glavonic E; Dragicevic N; Ivkovic S
Life Sci; 2023 Aug; 326():121803. PubMed ID: 37245840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
